Cargando…
Corrigendum: Novel Therapeutic Strategies for Dyslipidemia: First Report of Inclisiran Therapy in a Kidney Transplanted Patient
Autores principales: | Ueberdiek, Lars, Jehn, Ulrich, Pavenstädt, Hermann, Gebauer, Katrin, Reuter, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078348/ https://www.ncbi.nlm.nih.gov/pubmed/37035107 http://dx.doi.org/10.3389/ti.2023.11313 |
Ejemplares similares
-
Novel Therapeutic Strategies for Dyslipidemia: First Report of Inclisiran Therapy in a Kidney Transplanted Patient
por: Ueberdiek, Lars, et al.
Publicado: (2023) -
First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient
por: Jehn, Ulrich, et al.
Publicado: (2022) -
The Tacrolimus Metabolism Rate and Dyslipidemia after Kidney Transplantation
por: Thölking, Gerold, et al.
Publicado: (2021) -
Inclisiran: a novel drug for the treatment of dyslipidemia
por: Nadeem, Abdullah, et al.
Publicado: (2023) -
Fast Tacrolimus Metabolism Does Not Promote Post-Transplant Diabetes Mellitus after Kidney Transplantation
por: Jehn, Ulrich, et al.
Publicado: (2022)